The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Shahrokh F. Shariat

Department of Urology

University of Texas Southwestern Medical Center

Dallas

Texas

USA

[email]@utsouthwestern.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2004 - 2008
  • University of Texas Southwestern, Dallas, USA. 2008
  • Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada. 2008
  • University of Texas Southwestern Medical Center, Department of Urology, 5323 Harry Hines Boulevard, Dallas, USA. 2007

References

  1. Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. Shariat, S.F., Trinh, Q.D., Morey, A.F., Stage, K.H., Roehrborn, C.G., Valiquette, L., Karakiewicz, P.I. J. Trauma (2008) [Pubmed]
  2. Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators. Shariat, S.F., Bolenz, C., Karakiewicz, P.I. Eur. Urol. (2008) [Pubmed]
  3. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Shariat, S.F., Lamb, D.J., Iyengar, R.G., Roehrborn, C.G., Slawin, K.M. Clin. Cancer Res. (2008) [Pubmed]
  4. Features and outcomes of patients with grade IV renal injury. Shariat, S.F., Jenkins, A., Roehrborn, C.G., Karam, J.A., Stage, K.H., Karakiewicz, P.I. BJU Int. (2008) [Pubmed]
  5. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. Shariat, S.F., Walz, J., Roehrborn, C.G., Zlotta, A.R., Perrotte, P., Suardi, N., Saad, F., Karakiewicz, P.I. J. Clin. Oncol. (2008) [Pubmed]
  6. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. Shariat, S.F., Svatek, R.S., Kabbani, W., Walz, J., Lotan, Y., Karakiewicz, P.I., Roehrborn, C.G. BJU Int. (2008) [Pubmed]
  7. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Shariat, S.F., Karakiewicz, P.I., Ashfaq, R., Lerner, S.P., Palapattu, G.S., Cote, R.J., Sagalowsky, A.I., Lotan, Y. Cancer (2008) [Pubmed]
  8. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. Shariat, S.F., Karam, J.A., Margulis, V., Karakiewicz, P.I. BJU Int. (2008) [Pubmed]
  9. Molecular markers in bladder cancer. Shariat, S.F., Karam, J.A., Lerner, S.P. Curr. Opin. Urol (2008) [Pubmed]
  10. Nomograms for bladder cancer. Shariat, S.F., Margulis, V., Lotan, Y., Montorsi, F., Karakiewicz, P.I. Eur. Urol. (2008) [Pubmed]
  11. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. Shariat, S.F., Walz, J., Roehrborn, C.G., Montorsi, F., Jeldres, C., Saad, F., Karakiewicz, P.I. J. Urol. (2008) [Pubmed]
  12. Inventory of prostate cancer predictive tools. Shariat, S.F., Karakiewicz, P.I., Margulis, V., Kattan, M.W. Curr. Opin. Urol (2008) [Pubmed]
  13. Notice of duplicate publication: "Potentially harmful effect of a testosterone dietary supplement on prostate cancer growth and metastasis" (arch intern med. 2008;168[2]:235-236). Shariat, S.F., Roehrborn, C.G., Lamb, D.J., Slawin, K.M. Arch. Intern. Med. (2008) [Pubmed]
  14. Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. Shariat, S.F., Roehrborn, C.G., Karakiewicz, P.I., Dhami, G., Stage, K.H. J. Trauma (2007) [Pubmed]
  15. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Shariat, S.F., Ashfaq, R., Karakiewicz, P.I., Saeedi, O., Sagalowsky, A.I., Lotan, Y. Cancer (2007) [Pubmed]
  16. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. Shariat, S.F., Bensalah, K., Karam, J.A., Roehrborn, C.G., Gallina, A., Lotan, Y., Slawin, K.M., Karakiewicz, P.I. Clin. Cancer Res. (2007) [Pubmed]
  17. Blood biomarkers for prostate cancer detection and prognosis. Shariat, S.F., Karam, J.A., Roehrborn, C.G. Future. Oncol (2007) [Pubmed]
  18. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. Shariat, S.F., Park, S., Trinh, Q.D., Roehrborn, C.G., Slawin, K.M., Karakiewicz, P.I. J. Urol. (2007) [Pubmed]
  19. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Shariat, S.F., Ashfaq, R., Sagalowsky, A.I., Lotan, Y. Urol. Oncol. (2007) [Pubmed]
  20. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Shariat, S.F., Palapattu, G.S., Karakiewicz, P.I., Rogers, C.G., Vazina, A., Bastian, P.J., Schoenberg, M.P., Lerner, S.P., Sagalowsky, A.I., Lotan, Y. Eur. Urol. (2007) [Pubmed]
  21. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Shariat, S.F., Palapattu, G.S., Karakiewicz, P.I., Rogers, C.G., Vazina, A., Bastian, P.J., Schoenberg, M.P., Lerner, S.P., Sagalowsky, A.I., Lotan, Y. Eur. Urol. (2007) [Pubmed]
  22. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. Shariat, S.F., Ashfaq, R., Sagalowsky, A.I., Lotan, Y. J. Urol. (2007) [Pubmed]
  23. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. Shariat, S.F., Roehrborn, C.G., McConnell, J.D., Park, S., Alam, N., Wheeler, T.M., Slawin, K.M. J. Clin. Oncol. (2007) [Pubmed]
  24. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Shariat, S.F., Zlotta, A.R., Ashfaq, R., Sagalowsky, A.I., Lotan, Y. Mod. Pathol. (2007) [Pubmed]
  25. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. Shariat, S.F., Abdel-Aziz, K.F., Roehrborn, C.G., Lotan, Y. Eur. Urol. (2006) [Pubmed]
  26. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. Shariat, S.F., Marberger, M.J., Lotan, Y., Sanchez-Carbayo, M., Zippe, C., Lüdecke, G., Boman, H., Sawczuk, I., Friedrich, M.G., Casella, R., Mian, C., Eissa, S., Akaza, H., Serretta, V., Huland, H., Hedelin, H., Raina, R., Miyanaga, N., Sagalowsky, A.I., Roehrborn, C.G., Karakiewicz, P.I. J. Urol. (2006) [Pubmed]
  27. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Shariat, S.F., Ashfaq, R., Sagalowsky, A.I., Lotan, Y. Hum. Pathol. (2006) [Pubmed]
  28. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. Shariat, S.F., Karakiewicz, P.I., Palapattu, G.S., Lotan, Y., Rogers, C.G., Amiel, G.E., Vazina, A., Gupta, A., Bastian, P.J., Sagalowsky, A.I., Schoenberg, M.P., Lerner, S.P. J. Urol. (2006) [Pubmed]
  29. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. Shariat, S.F., Zippe, C., Lüdecke, G., Boman, H., Sanchez-Carbayo, M., Casella, R., Mian, C., Friedrich, M.G., Eissa, S., Akaza, H., Sawczuk, I., Serretta, V., Huland, H., Hedelin, H., Rupesh, R., Miyanaga, N., Sagalowsky, A.I., Wians, F., Roehrborn, C.G., Lotan, Y., Perrotte, P., Benayoun, S., Marberger, M.J., Karakiewicz, P.I. J. Urol. (2005) [Pubmed]
  30. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Shariat, S.F., Herman, M.P., Casella, R., Lotan, Y., Karam, J.A., Stenman, U.H. Eur. Urol. (2005) [Pubmed]
  31. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Shariat, S.F., Matsumoto, K., Casella, R., Jian, W., Lerner, S.P. Eur. Urol. (2005) [Pubmed]
  32. Gastrointestinal hemorrhage as first manifestation of metastatic testicular tumor. Shariat, S.F., Duchene, D., Kabbani, W., Mucher, Z., Lotan, Y. Urology (2005) [Pubmed]
  33. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Shariat, S.F., Lotan, Y., Saboorian, H., Khoddami, S.M., Roehrborn, C.G., Slawin, K.M., Ashfaq, R. Cancer (2004) [Pubmed]
  34. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Shariat, S.F., Casella, R., Wians, F.H., Ashfaq, R., Balko, J., Sulser, T., Gasser, T.C., Sagalowsky, A.I. Eur. Urol. (2004) [Pubmed]
 
WikiGenes - Universities